Homocysteine and arterial thrombosis: Challenge and opportunity

Summary

The correlation between homocysteine and vascular disease has been assessed in several clinical studies that demonstrated that elevation of plasma total homocysteine (tHcy) was an independent risk factor for atheriosclerotic disease. Major advances of homocysteine metabolism disorders have been made during the last few years, encompassing the rare homozygous enzyme deficiencies, as well as more common milder abnormalities. In experimental and clinical studies, a homocysteine-mediated oxidant stress has been shown to trigger platelet activation, in turn leading to a tendency to thrombosis, in patients with severe hyperhomocysteinaemia. Likewise, the hypomethylation hypothesis on acquired hyperhomocysteinaemia (chronic renal disease) and the interrelationship between hyperhomocysteinaemia and impaired fibrinolysis, have added further biological plausibility to the role for hyperhomocysteinaemia in vascular medicine. However, whether hyperhomocysteinaemia is causal or a marker of vascular disease, and whether plasma tHcy is only an indicator of the metabolic status remains to be clarified. The role of the intake of some vitamins (folic acid, vit.B₁₂, vit.B₆) on cardiovascular disease (CVD) is poorly understood: in spite of the lowering of homocysteine (Hcy) levels, vitamin supplementation failed to exert significant effects on cardiovascular risk. On the other hand, although some lipid-modifying treatments increase Hcy levels in diabetics, there is no evidence that this attenuates the beneficial effects of such treatments on the cardiovascular risk. Because of these uncertainties in the area, the data available do not provide support for routine screening and treatment for elevated Hcy to prevent CVD.

Keywords

Homocysteine - arterial thrombosis - folate

• References

• 1 McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
• 2 Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.
• 3 Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease.. In Francis RBL editor. Atherosclerotic cardiovascular disease hemostasis and endothelial function. Marcel Dekker; 1992: 183-236.
• 4 Boushey CJ, Beresford SA, Omenn GS. at al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-1057.
• 5 Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect?. Am J Clin Nutr 2000; 72: 315-323.
• 6 Ueland PM, Refsum H, Beresford SA. et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-332.
• 7 Brattstrom L, Israelsson B, Lindgarde F. et al. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cyst-athionine beta-synthase deficiency. Metabolism 1988; 37: 175-178.
• 8 Brattstrom L, Wilcken DE, Ohrvik J. et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520-2526.
• 9 Klerk M, Verhoef P, Clarke R. et al. MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis. J Am Med Assoc 2002; 288: 2023-2031.
• 10 Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217-246.
• 11 Selhub J. The Many Facets of Hyperhomocysteinemia: Studies from the Framing-ham Cohorts. J Nutr 2006; 136: 1726S-1730S.
• 12 Casas JP, Bautista LE, Smeeth L. et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005; 365: 224-232.
• 13 Homocysteine Studies Collaboration.. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002; 288: 2015-2022.
• 14 Lentz SR, Sobey CG, Piegors DJ. et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24-29.
• 15 Coppola A, Davi G, De Stefano V. et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 243-254.
• 16 Stamler S, Osborne JA, Jaraki M. et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
• 17 Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
• 18 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 19 Di Minno G, Davi G, Margaglione M. et al. Abnormalty high thromboxane bio-synthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin invest 1993; 92: 1400-1406.
• 20 Davi G, Di Minno G, Coppola A. et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-1128.
• 21 Coppola A, D’Angelo A, Fermo I. et al. Reduced in vivo oxidative stress following 5-methyl-tetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. Br J Haematol 2005; 131: 100-108.
• 22 Welch GN, Upchurch Jr GR, Farivar RS. et al. Homocysteine-induced nitric oxide production in vascular smooth cells by NF-κB dependent transcriptional activity of Nos2. Proc Am Assoc Phys 1998; 110: 22-31.
• 23 Di Minno G, Coppola A, Cerbone AM. et al. Hirudin does not affect the abnormally high thromboxane biosynthesis in homozygous homocystinuria. Fibrinolysis 1996; 10 (Suppl. 01) 36.
• 24 Di Minno G, Coppola A, Mancini FP. et al. Homocysteine, platelet function and thrombosis. Haematologica 1999; 84 Suppl EHA-4 61-63.
• 25 Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005; 94: 907-915.
• 26 Perna A, Ingrosso D, Zappia V. et al. Enzymatic methyl esterification of memebrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S.adenosylhomocysteine J Clin Invest 1993; 91: 2497-2503.
• 27 Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomoduiin and enhances thrombomodulin expression in human umbilical vein endothehal cells. Blood 1992; 79: 2930-2936.
• 28 Fryer RH, Wilson BD, Gubler DB. et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-1333.
• 29 Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulphate expression in cultured porcine aortic endothelial celis. J Clin Invest 1993; 92: 1381-1386.
• 30 Hajjar KA. Homocysteine-induced modulation of tissue piasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879.
• 31 Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285-1289.
• 32 Hofmann MA, Lalla E, Lu Y. et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-683.
• 33 Tsai JC, Perrella MA, Yoshizumi M. et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
• 34 Buemi M, Marino D, Di Pasquale G. et al. Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res 2001; 104: 207-213.
• 35 Midorikawa S, Sanada H, Hashimoto S. et al. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. Biochem Biophys Res Commun 2000; 272: 182-185.
• 36 Kuch B, Bobak M, Fobker M. et al. Associations between homocysteine and coagulation factors—a cross-sectional study in two populations of central Europe. Thromb Res 2001; 103: 265-273.
• 37 Schreiner PJ, Wu KK, Malinow MR. et al. Hyperhomocyst(e)inemia and hemostatic factors: the atherosclerosis risk in communities study. Ann Epidemiol 2002; 12: 228-236.
• 38 Tofler GH, D’Agostino RB, Jacques PF. et al. Association between increased homo-cysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost 2002; 88: 799-804.
• 39 Speidl WS, Nikfardjam M, Niessner A. et al. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction. Thrombosis Res 2007; 119: 331-336.
• 40 Bozic M, Stegnar M, Fermo I. et al. Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism. Thromb Res 2000; 100: 271-278.
• 41 Bienvenu T, Ankri A, Chadefaux B. et al. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993; 70: 123-129.
• 42 Kristensen B, Malm J, Nilsson TK. et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999; 30: 974-980.
• 43 Freyburger G, Labrouche S, Sassoust G. et al. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost 1997; 77: 466-471.
• 44 Labinjoh C, Newby DE, Wilkinson IB. et al. Effects of acute methionine loading and vitamin C on endogenous fibrinolysis, endothelium-dependent vasomotion and platelet aggregation. Clin Sci 2001; 100: 127-135.
• 45 Colucci M, Cattaneo M, Martinelli I. et al. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost 2008; 06: 1571-1577.
• 46 Lauricella AM, Quintana IL, Kordich LC. Effects of homocysteine thiol group on fibrin networks: another possible mechanism of harm. Thromb Res 2002; 107: 75-79.
• 47 Lauricella AM, Quintana I, Castanon M. et al. Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 2006; 17: 181-186.
• 48 Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003; 01: 300-306.
• 49 Undas A, Brozek J, Jankowski M. et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26: 1397-1404.
• 50 Marchi R, Carvajal Z, Weisel JW. Comparison of the effect of different homocysteine concentrations on clot formation using human plasma and purified fibrinogen. Thromb Haemost 2008; 99: 451-452.
• 51 Selhub J, Jacques PF, Bostom AG. et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332: 286-291.
• 52 Verhoef P, Kok FJ, Kruyssen DA. et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-995.
• 53 Van den Berg M, Stehouwer CD, Bierdrager E. et al. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-171.
• 54 Wierzbicki A. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007; 04: 143-50.
• 55 Graham IM, Daly LE, Refsum HM. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 1997; 277: 1775-1781.
• 56 Stampfer MJ, Malinow MR, Willett WC. et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877-881.
• 57 Arnesen E, Refsum H, Bonaa KH. et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-709.
• 58 Wald NJ, Watt HC, Law MR. et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-867.
• 59 Bots ML, Launer LJ, Lindemans J. et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Arch Intern Med 1999; 159: 38-44.
• 60 Perry IJ, Refsum H, Morris RW. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398.
• 61 Chasan-Taber L, Selhub J, Rosenberg IH. et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-143.
• 62 Evans RW, Shaten BJ, Hempel JD. et al. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-1953.
• 63 Folsom AR, Nieto FJ, McGovern PG. et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-210.
• 64 Alfthan G, Pekkanen J, Jauhiainen M. et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
• 65 Verhoef P, Hennekens CH, Malinow MR. et al. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994; 25: 1924-1930.
• 66 Verhoef P, Hennekens CH, Allen RH. et al. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass sugery. Am J Cardiol 1997; 79: 799-801.
• 67 Brilakis ES, McConnell JP, Ballman KV. et al. Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. Atherosclerosis 2002; 165: 375-381.
• 68 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002; 325: 1202-1209.
• 69 Lewis SJ, Ebrahim S, DaveySmith G. Meta-analysis of MTHFR 677C T polymorphism and coronary heart disease: does totality of evidence support a causal role of homocysteine and preventive potential of folate?. Br Med J 2005; 331: 1053.
• 70 Ford ES, Smith SJ, Stroup KK. et al. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002; 31: 59-70.
• 71 B-Vitamin Treatment Trialists’ Collaboration.. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006; 151: 282-287.
• 72 Toole JF, Malinow MR, Chambless LE. et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc 2004; 291: 565-575.
• 73 Spence JD, Ban H, Chambless LE. et al. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke 2005; 36: 2404-2409.
• 74 Bonaa KH, Njolstad I, Ueland PM. et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588.
• 75 The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators.. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
• 76 Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease. J Am Coll Cardiol 2006; 48: 914-923.
• 77 Schnyder G, Roffi M, Pin R. et al. Decreased rate of coronary stenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-1600.
• 78 Schnyder G, Roffi M, Flammer Y. et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12 and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. J Am Med Assoc 2002; 288: 973-979.
• 79 Lange H, Suryapranata H, de Luca G. et al. Folate therapy and in-stent stenosis after coronary stenting. N Engl J Med 2004; 350: 2673-2681.
• 80 Bazzano LA, Reynolds K, Holder KN. et al. Effect of folic acid supplementation on risk of cardiovascular diseases. A meta-analysis of randomized controlled trials. J Am Med Assoc 2006; 296: 2720-2726.
• 81 Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Current Atherosclerosis Reports 2006; 08: 100-106.
• 82 Nygard O, Refsum H, Ueland PM. et al. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland homocysteine study. Am J Clin Nutr 1998; 67: 263-270.
• 83 Eikelboom JW, Lonn E, Genest Jr J. et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
• 84 Jamison RL, Hartigan P, Kaufman JS. et al Veterans Affairs Site Investigators.. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. J Am Med Assoc 2007; 298: 1163-1170.
• 85 Albert CM, Cook NR, Gaziano JM. et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high rsk for cardiovascular disease: a randomized trial. J Am Med Assoc 2008; 299: 2027-2036.
• 86 Ebbing M, Bleie Ø, Ueland PM. et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. J Am Med Assoc 2008; 300: 795-804.
• 87 Martí-Carvajal AJ, Solà I, Lathyris D. et al. Homocysteine lowering interventions for preventing cardiovascular events (Review). Cochrane Database of Systematic Reviews. 2009 4: CD006612. DOI:10.1002/14651858. CD006612.pub2
• 88 Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid lowering drugs on plasma homocysteine levels. Exp Opin Drug Saf 2004; 03: 101-111.
• 89 Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005; 05: 124-139.
• 90 De Souza C, Keebler M, McNamara DB. et al. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 2002; 62: 605-616.
• 91 Westphal S, Rading A, Luley C. et al. Antihypertensive treatment and homocysteine concentrations. Metabolism 2003; 52: 261-263.
• 92 Tomkin GH, Hadden DR, Weaver JA. et al. Vitamin-B12 status of patients on long-term metformin therapy. Br Med J 1971; 02: 685-687.
• 93 Carlsen SM, Folling I, Grill V. et al. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997; 57: 521-527.
• 94 Bauman WA, Shaw S, Jayatilleke E. et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23: 1227-1231.
• 95 Kilicdag EB, Bagis T, Zeyneloglu HB. et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Rep 2005; 20: 894-899.
• 96 De Rosa G, D’Angelo A, Ragonesi PD. et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383.
• 97 Giral P, Bruckert E, Jacob N. et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001; 154: 421-427.
• 98 Diabetes Atherosclerosis Intervention Study Investigators.. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
• 99 Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004; 93: 848-853.
• 100 The FIELD study investigators.. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.